{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:48:49Z","timestamp":1794358129788,"version":"4.9.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biotechnology Advances"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.biotechadv.2025.108612","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T11:56:27Z","timestamp":1747914987000},"page":"108612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Advanced therapy medicinal products development - from guidelines to medicines in the market"],"prefix":"10.1016","volume":"83","author":[{"given":"Catarina","family":"Frederico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Concei\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9vio","family":"N\u00f3brega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana S.","family":"Mendon\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.biotechadv.2025.108612_bb0005","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/sctm.19-0019","article-title":"Convergence of cell pharmacology and drug delivery","volume":"8","author":"Aijaz","year":"2019","journal-title":"Stem Cells Transl. Med."},{"issue":"10","key":"10.1016\/j.biotechadv.2025.108612_bb0010","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.3390\/vaccines9101196","article-title":"COVID-19 vaccine platforms: challenges and safety contemplations","volume":"9","author":"Al-Jighefee","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0015","article-title":"Gene editing and genotoxicity: targeting the off-targets","volume":"2","author":"Blattner","year":"2020","journal-title":"Front. Genome Edit."},{"issue":"9","key":"10.1016\/j.biotechadv.2025.108612_bb0020","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3390\/pharmaceutics13091341","article-title":"Biomaterials for soft tissue repair and regeneration: A focus on Italian research in the field","volume":"13","author":"Bonferoni","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.biotechadv.2025.108612_bb0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jcyt.2012.10.008","article-title":"Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry","volume":"15","author":"Bravery","year":"2013","journal-title":"Cytotherapy"},{"issue":"3","key":"10.1016\/j.biotechadv.2025.108612_bb0030","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.drudis.2018.12.007","article-title":"Hurdles in gene therapy regulatory approval: a retrospective analysis of European marketing authorization applications","volume":"24","author":"Carvalho","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0035","series-title":"Guideline on the Quality, Non-Clinical and Clinical Aspects of Gene Therapy Medicinal Products. EMA\/CAT\/80183\/2014","author":"CAT","year":"2018"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0040","series-title":"Committee for Advanced Therapies (CAT) - Rules of Procedure. EMA\/CAT\/454446\/2008 rev. 5","author":"CAT","year":"2022"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0045","series-title":"CAT quarterly highlights and approved ATMPs - April 2024. EMA\/CAT\/177024\/2024","author":"CAT","year":"2024"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0050","series-title":"Guideline on Quality, Non-clinical and Clinical Requirements for Investigational Advanced Therapy Medicinal Products in Clinical Trials. EMA\/CAT\/123573\/2024","author":"CAT","year":"2024"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0055","first-page":"3","article-title":"Comission directive 2009\/120\/EC of 14 September 2009 amending directive 2001\/83\/EC of the European Parliament and of the council on the community code relating to medicinal products for human use as regards advanced therapy medicinal products","volume":"L242,","author":"CD","year":"2009","journal-title":"Off. J. Eur. Union"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0060","series-title":"Guideline on human cell-based medicinal products. EMEA\/CHMP\/410869\/2006","author":"CHMP","year":"2008"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0065","series-title":"Guideline on the non-clinical studies required before first clinical use of gene therapy medicinal products. EMEA\/CHMP\/GTWP\/125459\/2006","author":"CHMP","year":"2008"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0070","series-title":"European Medicines Agency Recommends First Gene Therapy for Approval","author":"CHMP","year":"2012"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0075","series-title":"First Oncolytic Immunotherapy Medicine Recommended for Approval: Advanced Therapy Medicine Imlygic Indicated to Treat Certain Stages of Melanoma. EMA\/CHMP\/692401\/2015","author":"CHMP","year":"2015"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0080","series-title":"Guideline on Strategies to Identify and Mitigate Risks for First-in-Human and Early Clinical Trials With Investigational Medicinal Products. EMEA\/CHMP\/SWP\/28367\/07 Rev. 1","author":"CHMP","year":"2017"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0085","series-title":"Adults With Early Manifesting Huntington\u2019s Disease","article-title":"Safety and Tolerability Study With VY-HTT01","author":"ClinicalTrials.gov","year":"2021"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0090","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.831091","article-title":"Genetic modifications that expand oncolytic virus potency","volume":"9","author":"Cristi","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.biotechadv.2025.108612_bb0100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.omtm.2019.01.010","article-title":"EU regulatory pathways for ATMPs: standard, accelerated and adaptive pathways to marketing authorisation","volume":"13","author":"Detela","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biotechadv.2025.108612_bb0105","first-page":"121","article-title":"Regulation (EC) N.\u00b0 1394\/2007 of the European Parliament and of the council of 13 November 2007 on advanced therapy medicinal products and amending directive 2001\/83\/EC and regulation (EC) N.\u00b0 726\/2004","volume":"L324","author":"EC.","year":"2007","journal-title":"Off. J. Eur. Union"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.756029","article-title":"Cell therapy: types, regulation, and clinical benefits","volume":"8","author":"El-Kadiry","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.biotechadv.2025.108612_bb0115","series-title":"Guideline on Non-clinical Testing for Inadvertent Germline Transmission of Gene Transfer Vectors. EMEA\/273974\/2005","author":"EMA","year":"2006"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0120","series-title":"European Public Assessment Report for Chondrocelect. Procedure No. EMEA\/H\/C\/000878","author":"EMA","year":"2009"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0125","series-title":"Summary of Product Characteristics (ChondroCelect)","author":"EMA","year":"2012"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0130","series-title":"European Public Assessment Report for MACI. Procedure No. EMEA\/H\/C\/002522\/0000. EMA\/25287\/2013","author":"EMA","year":"2013"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0135","series-title":"MACI: Matrix Applied Characterised Autologous Cultured Chondrocy. EMA\/282918\/2013","author":"EMA","year":"2013"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0140","series-title":"Reflection Paper on Management of Clinical Risks Deriving From Insertional Mutagenesis. EMA\/CAT\/190186\/2012","author":"EMA","year":"2013"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0145","series-title":"Reflection Paper on Clinical Aspects Related to Tissue Engineered Products. EMA\/CAT\/573420\/2009","author":"EMA","year":"2014"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0150","series-title":"Holoclar: Ex vivo Expanded Autologous Human Corneal Epithelial Cells Containing Stem Cells. (EMA\/6865\/2015)","author":"EMA","year":"2015"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0155","series-title":"Summary of Product Characteristics (Imlygic)","author":"EMA","year":"2016"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0160","series-title":"Summary of Product Characteristics (Strimvelis)","author":"EMA","year":"2016"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0165","series-title":"Glybera: overview","author":"EMA","year":"2017"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0170","series-title":"Summary of Product Characteristics (Alofisel)","author":"EMA","year":"2018"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0175","series-title":"Summary of Product Characteristics (Luxturna)","author":"EMA","year":"2018"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0180","series-title":"First Two CAR-T Cell Medicines Recommended for Approval in the European Union. EMA\/431116\/2018","author":"EMA","year":"2018"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0185","series-title":"Summary of Product Characteristics (Yescarta)","author":"EMA","year":"2018"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0190","series-title":"Summary of Product Characteristics (Kymriah)","author":"EMA","year":"2018"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0195","series-title":"Summary of product characteristics (Zolgensma)","author":"EMA","year":"2020"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0200","series-title":"Guideline on Quality, Non-clinical and Clinical Aspects of Medicinal Products Containing Genetically Modified Cells. EMA\/CAT\/GTWP\/671639\/2008 Rev. 1 - corr","author":"EMA","year":"2020"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0205","series-title":"Spherox (Spheroids of Human Autologous Matrix Associated Chondrocytes): An Overview of Spherox and Why It Is Authorised in the EU. EMA\/326451\/2021","author":"EMA","year":"2021"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0210","series-title":"Summary of Product Characteristics (Glybera)","author":"EMA","year":"2021"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0215","series-title":"EMA\u2019S Guide on Advanced Therapy Medicinal Products: Non-Clinical Development","author":"EMA","year":"2021"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0220","series-title":"EMA\u2019S Guide on Advanced Therapy Medicinal Products: Clinical Development","author":"EMA","year":"2021"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0225","series-title":"EMA\u2019S Guide on Advanced Therapy Medicinal Products: Quality","author":"EMA","year":"2021"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0230","series-title":"Ebvallo (Tabelecleucel) - An Overview of Ebvallo and Why It is Authorised in the EU. EMA\/852064\/2022","author":"EMA","year":"2022"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0235","series-title":"Summary of Product Characteristics (Upstaza)","author":"EMA","year":"2022"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0240","series-title":"Summary of Product Characteristics (Tecartus)","author":"EMA","year":"2022"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0245","series-title":"Summary of Product Characteristics (Breyanzi)","author":"EMA","year":"2022"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0250","series-title":"Summary of Product Characteristics (Hemgenix)","author":"EMA","year":"2023"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0255","series-title":"Casgevy (Exagamglogene Autotemcel): An Overview of Casgevy and Why it is Authorised in the EU","author":"EMA","year":"2024"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0260","series-title":"Abecma (Idecabtagene Vicleucel): An Overview of Abecma and Why It is Authorised in the EU","author":"EMA","year":"2024"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0265","series-title":"Carvykti (ciltacabtagene autoleucel): An Overview of Carvykti and Why It is Authorised in the EU. EMA\/145227\/2024","author":"EMA","year":"2024"},{"issue":"5","key":"10.1016\/j.biotechadv.2025.108612_bb0270","first-page":"506","article-title":"NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells","volume":"10","author":"Emerich","year":"2008","journal-title":"Curr. Opin. Mol. Ther."},{"issue":"1","key":"10.1016\/j.biotechadv.2025.108612_bb0275","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/vaccines10010062","article-title":"A narrative review of COVID-19 vaccines","volume":"10","author":"Eroglu","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2017.00053","article-title":"Advanced therapy medicinal products for rare diseases: state of play of incentives supporting development in Europe","volume":"4","author":"Farkas","year":"2017","journal-title":"Front. Med."},{"key":"10.1016\/j.biotechadv.2025.108612_bb0285","first-page":"1","article-title":"Current and possible future therapeutic options for Huntington\u2019s disease","volume":"14","author":"Ferguson","year":"2022","journal-title":"J. Centr. Nerv. Syst. Dis."},{"issue":"6","key":"10.1016\/j.biotechadv.2025.108612_bb0290","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3390\/cancers13061383","article-title":"Talimogene Laherparepvec (T-VEC): an Intralesional Cancer immunotherapy for advanced melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21691401.2017.1391820","article-title":"Ciliary neurotrophic factor (CNTF) delivery to retina: an overview of current research advancements","author":"Ghasemi","year":"2017","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"1","key":"10.1016\/j.biotechadv.2025.108612_bb0300","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1535676019899502","article-title":"Viral vector systems for gene therapy: A comprehensive literature review of progress and biosafety challenges","volume":"25","author":"Ghosh","year":"2020","journal-title":"Appl. Biosafety"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0305","series-title":"Handbook of Cell and Gene Therapy: From Proof-of-Concept through Manufacturing to Commercialization","first-page":"104","article-title":"Analytical methods for in-process testing and product release","author":"Haig","year":"2023"},{"issue":"1","key":"10.1016\/j.biotechadv.2025.108612_bb0310","doi-asserted-by":"crossref","DOI":"10.3402\/jmahp.v4.31036","article-title":"Advanced therapy medicinal products: current and future perspectives","volume":"4","author":"Hanna","year":"2016","journal-title":"J. Market Access Health Policy"},{"issue":"1","key":"10.1016\/j.biotechadv.2025.108612_bb0315","doi-asserted-by":"crossref","first-page":"32232","DOI":"10.3402\/jmahp.v4.32232","article-title":"Risk of discontinuation of advanced therapy medicinal products clinical trials","volume":"4","author":"Hanna","year":"2016","journal-title":"J. Market Access Health Policy"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0320","series-title":"Handbook of Cell and Gene Therapy: From Proof-of-Concept through Manufacturing to Commercialization","first-page":"1","article-title":"History of gene therapy products","author":"Heelan","year":"2023"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0325","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.omtm.2018.10.003","article-title":"Challenges in advanced therapy medicinal product development: a survey among companies in Europe","volume":"11","author":"Ten Ham","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biotechadv.2025.108612_bb0330","series-title":"ICH Guideline S6 (R1) \u2013 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. EMA\/CHMP\/ICH\/731268\/1998","author":"ICH","year":"1998"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0335","series-title":"ICH Considerations - General Principles to Address Virus and Vector Shedding. EMEA\/CHMP\/ICH\/449035\/2009","author":"ICH","year":"2009"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0340","series-title":"ICH Considerations - Oncolytic Viruses. EMEA\/CHMP\/ICH\/607698\/2008","author":"ICH","year":"2009"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0345","series-title":"ICH S12 - Guideline on Nonclinical Biodistribution Considerations for Gene Therapy Products. EMA\/CHMP\/ICH\/318372\/2021","author":"ICH","year":"2023"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0350","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fphar.2019.00921","article-title":"Regulatory framework for advanced therapy medicinal products in Europe and United States","volume":"10","author":"Iglesias-Lopez","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.biotechadv.2025.108612_bb0355","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.stem.2023.07.004","article-title":"Regulation of advanced therapies in Europe: are we on the right track?","volume":"30","author":"Izeta","year":"2023","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.biotechadv.2025.108612_bb0360","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1089\/ten.teb.2022.0094","article-title":"Issues with tissues: trends in tissue-engineered products in clinical trials in the European Union","volume":"29","author":"Joyce","year":"2023","journal-title":"Tissue Eng. Part B Rev."},{"key":"10.1016\/j.biotechadv.2025.108612_bb0365","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.addr.2020.09.012","article-title":"Engineered tissues and strategies to overcome challenges in drug development","volume":"158","author":"Khalil","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.biotechadv.2025.108612_bb0370","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s12015-021-10262-3","article-title":"Review of the current trends in clinical trials involving induced pluripotent stem cells","volume":"18","author":"Kim","year":"2022","journal-title":"Stem Cell Rev. Rep."},{"issue":"8","key":"10.1016\/j.biotechadv.2025.108612_bb0375","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.medj.2022.05.001","article-title":"Understanding CAR T cell-tumor interactions: paving the way for successful clinical outcomes","volume":"3","author":"Korell","year":"2022","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.biotechadv.2025.108612_bb0380","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1089\/ten.teb.2009.0449","article-title":"Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the United States","volume":"16","author":"Lee","year":"2010","journal-title":"Tissue Eng. Part B Rev."},{"issue":"3","key":"10.1016\/j.biotechadv.2025.108612_bb0385","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3390\/pharmaceutics13030347","article-title":"Advanced therapy medicinal products for the eye: definitions and regulatory framework","volume":"13","author":"L\u00f3pez-Paniagua","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0390","series-title":"Handbook about Regulatory Guidelines and Procedures for the Preclinical and Clinical Stages of Advanced Therapy Medicinal Products (ATMPs)","author":"Luria","year":"2016"},{"issue":"8","key":"10.1016\/j.biotechadv.2025.108612_bb0395","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11095-018-2437-y","article-title":"Preclinical development of cell-based products: a European regulatory science perspective","volume":"35","author":"McBlane","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biotechadv.2025.108612_bb0400","series-title":"Handbook of Gene and Cell Therapy","first-page":"23","article-title":"Non-viral vectors for gene therapy","author":"N\u00f3brega","year":"2020"},{"key":"10.1016\/j.biotechadv.2025.108612_bb0405","series-title":"Handbook of Gene and Cell Therapy","first-page":"38","article-title":"Viral vectors for gene therapy","author":"N\u00f3brega","year":"2020"},{"issue":"S1","key":"10.1016\/j.biotechadv.2025.108612_bb0410","doi-asserted-by":"crossref","first-page":"51","DOI":"10.18609\/cgti.2019.007","article-title":"Non-viral vector mediated gene delivery: the outsider to watch out for in gene therapy","volume":"5","author":"Nyamay\u2019Antu","year":"2019","journal-title":"Cell and Gene Therapy Insights"},{"issue":"9","key":"10.1016\/j.biotechadv.2025.108612_bb0415","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3390\/vaccines11091448","article-title":"Oncolytic viruses: an inventory of shedding data from clinical trials and elements for the environmental risk assessment","volume":"11","author":"Onnockx","year":"2023","journal-title":"Vaccines"},{"issue":"8","key":"10.1016\/j.biotechadv.2025.108612_bb0420","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s11095-010-0136-4","article-title":"Gene therapy: a pharmacokinetic\/pharmacodynamic modelling overview","volume":"27","author":"Parra-Guill\u00e9n","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biotechadv.2025.108612_bb0425","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.757647","article-title":"Advanced therapy medicinal products\u2019 translation in Europe: a developers\u2019 perspective","volume":"9","author":"Pizevska","year":"2022","journal-title":"Front. Med."},{"issue":"3","key":"10.1016\/j.biotechadv.2025.108612_bb0430","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.fertnstert.2023.02.040","article-title":"The history, use, and challenges of therapeutic somatic cell and germline gene editing","volume":"120","author":"Ryu","year":"2023","journal-title":"Fertil. Steril."},{"issue":"1","key":"10.1016\/j.biotechadv.2025.108612_bb0435","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","article-title":"T cell receptor (TCR) signaling in health and disease","volume":"6","author":"Shah","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.biotechadv.2025.108612_bb0440","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/d41587-021-00023-5","article-title":"First COVID-19 DNA vaccine approved, others in hot pursuit","volume":"39","author":"Sheridan","year":"2021","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.biotechadv.2025.108612_bb0445","doi-asserted-by":"crossref","first-page":"10743","DOI":"10.1038\/s41467-024-53220-6","article-title":"PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial","volume":"15","author":"Stein","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biotechadv.2025.108612_bb0450","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.csbj.2020.08.031","article-title":"CRISPR-Cas systems: overview, innovations and applications in human disease research and gene therapy","volume":"18","author":"Xu","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"19\u201320","key":"10.1016\/j.biotechadv.2025.108612_bb0455","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1089\/hum.2020.156","article-title":"Aspects of gene therapy products using current genome-editing technology in Japan","volume":"31","author":"Yamaguchi","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.biotechadv.2025.108612_bb0460","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953410","article-title":"Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements","volume":"13","author":"Yun","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biotechadv.2025.108612_bb0465","article-title":"Engineered TCR-T cell immunotherapy in anticancer precision medicine: pros and cons","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.biotechadv.2025.108612_bb0470","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-021-00608-7","article-title":"Non-viral vectors in gene therapy: recent development, challenges, and prospects","volume":"23","author":"Zu","year":"2021","journal-title":"AAPS J."}],"container-title":["Biotechnology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0734975025000989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0734975025000989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T18:47:26Z","timestamp":1758998846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0734975025000989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":94,"alternative-id":["S0734975025000989"],"URL":"https:\/\/doi.org\/10.1016\/j.biotechadv.2025.108612","relation":{},"ISSN":["0734-9750"],"issn-type":[{"value":"0734-9750","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced therapy medicinal products development - from guidelines to medicines in the market","name":"articletitle","label":"Article Title"},{"value":"Biotechnology Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biotechadv.2025.108612","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108612"}}